ClinicalTrials.gov
ClinicalTrials.gov Menu

Magnesium to Reduce Implantable Cardioverter Defibrillator (ICD) Shocks and Improve Patient's Quality of Life.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00282620
Recruitment Status : Unknown
Verified March 2007 by Hartford Hospital.
Recruitment status was:  Recruiting
First Posted : January 27, 2006
Last Update Posted : November 20, 2007
Sponsor:
Information provided by:
Hartford Hospital

Brief Summary:
This study is being conducted to see if magnesium can reduce the number of shocks patients with ICDs experience and to see if magnesium supplementation improves patients quality of life.

Condition or disease Intervention/treatment Phase
Arrhythmia Quality of Life Hypomagnesemia Drug: Magnesium L-lactate Phase 4

Detailed Description:

Not all ICD shocks are for ventricular arrhythmias. Some patients receive shocks when they have arrhythmias in the atria (top chambers of the heart). These are called inapproriate shocks, but the pain is similar to the pain patients feel with an appropriate shock (a shock for a ventricular arrhythmia). This study is being conducted to determine if taking magnesium can reduce the number of shocks patients with ICDs experience and to see if magnesium supplementation improves patients quality of life. Magnesium's impact of the electrocardiogram (ECG) and intracellular magnesium concentrations will also be studied.

Comparison: Magnesium compared to placebo in patients with ICDs to evaluate the number of ICD shocks and patient perceived quality of life.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 240 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: The Adjuvant Magnesium Trial (AdMag): Assessment if the Impact of Oral Magnesium on ICD Firing and Quality of Life
Study Start Date : January 2006
Estimated Study Completion Date : June 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Shock
Drug Information available for: Magnesium
U.S. FDA Resources




Primary Outcome Measures :
  1. Cumulative occurrence of ICD shocks and patient perceived quality of life at baseline, 3,6,9, and 12 months

Secondary Outcome Measures :
  1. Change in QTc interval in the total population and the subgroup receiving class III antiarrhythmics at baseline, 3, 6, 9, 12 months.
  2. Intracellular magnesium concentrations at baseline, 3 and 12 months
  3. Incidence of supraventricular arrhythmias, ventricular arrhythmias, and sinus tachycardias at baseline, 3,6,9,12 months.
  4. Ventricular fibrillation cycle length and the variability in VFCL at baseline, 3,6,9,12 months
  5. Adverse events at basline, 3,6,9,12 months. Total Hospital Costs and Cost-effectiveness.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:newly implanted ICD or recent ICD shock (within 6 months) -

Exclusion Criteria:inability to swallow, a non-cardiac disease with a survival prognosis of less than 12 months, hypermagnesemia, a creatinine clearance less than 30mL/min, lactic acidosis or systemic acidosis syndrome, or previous intolerance to magnesium L-lactate.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00282620


Contacts
Contact: Jeffrey Kluger, MD 860-545-2883 Jkluger@harthosp.org
Contact: Charles M White, PharmD 860-545-2221 Cmwhite@harthosp.org

Locations
United States, Connecticut
Hartford Hospital Recruiting
Hartford, Connecticut, United States, 06102-5037
Contact: Jeffrey Kluger, MD    860-545-2883    JKluger@harthosp.org   
Contact: Charles M White, PharmD    860-545-2221    Cmwhite@harthosp.org   
Principal Investigator: Jeffrey Kluger, MD         
Sub-Investigator: Charles M White, PharmD         
Sub-Investigator: Nickole N Henyan, PharmD         
Sub-Investigator: Stephen D Sander, PharmD         
Sub-Investigator: Craig I Coleman, PharmD         
Sub-Investigator: Effie L Gillespie, PharmD         
Sub-Investigator: Christopher A Clyne, MD         
Sub-Investigator: William L Baker, PharmD         
Sponsors and Collaborators
Hartford Hospital
Investigators
Principal Investigator: Jeffrey Kluger, MD Hartford Hospital

ClinicalTrials.gov Identifier: NCT00282620     History of Changes
Other Study ID Numbers: KLUG001817HE
First Posted: January 27, 2006    Key Record Dates
Last Update Posted: November 20, 2007
Last Verified: March 2007

Keywords provided by Hartford Hospital:
Implantable Cardioverter Defibrillator
Magnesium
Electrocardiogram
Ventricular Arrhythmia